Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker TRAW · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to M… NCT07157007 · COVID - 19 Ratutrelvir (83-0060) non-randomised, Paxlovid | TRAW Traws Pharma, Inc. | Phase 2 | Completed was recruiting | 93 | Feb 16, 2026 | Registry ↗ |
| Aug 3, 2026 | Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers NCT07526506 · Healthy Volunteer TRX-100, Placebo | TRAW Traws Pharma, Inc. | Phase 1 | Recruiting | 32 | Sep 2026 | Registry ↗ |
| Mar 31, 2026 | Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model NCT07503405 · Influenza TRX-100, Placebo | TRAW Traws Pharma, Inc. | Phase 2 | Not yet recruiting | 165 | Nov 2026 | Registry ↗ |
| Mar 27, 2026 | This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil… NCT07371650 · Influenza TRX-100, Standard of Care (SOC) | TRAW Traws Pharma, Inc. | Phase 2 | Active, not recruiting | 105 | Dec 2026 | Registry ↗ |
| Jan 22, 2026 | Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-… NCT06402136 · Healthy Volunteers Only 83-0060, Placebo | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 57 | Aug 9, 2024 | Registry ↗ |
| Jan 21, 2026 | A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TR… NCT06757738 · Healthy Volunteer Study TRX-100, Placebo | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 66 | Jan 16, 2025 | Registry ↗ |
| Dec 12, 2023 | Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malign… NCT05705505 · Endometrioid Endometrial Cancer Narazaciclib, Letrozole 2.5mg | TRAW Traws Pharma, Inc. | Phase 1/2 | Unknown | 60 | Jan 2026 | Registry ↗ |
| Dec 7, 2023 | Study of ON 123300 in Patients With Advanced Cancer NCT04739293 · Solid Tumors, Adult ON123300 | TRAW Traws Pharma, Inc. | Phase 1 | Unknown | 36 | Oct 2024 | Registry ↗ |
| Sep 26, 2022 | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure… NCT02562443 · Myelodysplastic Syndrome, MDS rigosertib, Any approved or standard-of-care therapy | TRAW Traws Pharma, Inc. | Phase 3 | Terminated | 372 | Jul 26, 2020 | Registry ↗ |
| Jun 22, 2021 | Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors NCT02168725 · Neoplasms, Advanced Solid Tumor briciclib | TRAW Traws Pharma, Inc. | Phase 1 | Terminated | 26 | Dec 2015 | Registry ↗ |
| Jun 16, 2021 | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine NCT01926587 · Myelodysplastic Syndrome, Acute Myeloid Leukemia oral rigosertib, Azacitidine | TRAW Traws Pharma, Inc. | Phase 1/2 | Completed | 45 | Dec 8, 2020 | Registry ↗ |
| Jun 16, 2021 | Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs NCT01904682 · Myelodysplastic Syndromes Oral rigosertib | TRAW Traws Pharma, Inc. | Phase 2 | Completed | 45 | Dec 2020 | Registry ↗ |
| Jul 1, 2020 | Three Dosing Schedules of Oral Rigosertib in MDS Patients NCT02075034 · Myelodysplastic Syndrome rigosertib | TRAW Traws Pharma, Inc. | Phase 1 | Withdrawn | 0 | Aug 2019 | Registry ↗ |
| Jun 30, 2020 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidi… NCT01928537 · Myelodysplastic Syndromes, Refractory Anemia With Excess Bl… rigosertib sodium | TRAW Traws Pharma, Inc. | Phase 3 | Completed | 67 | Jun 29, 2017 | Registry ↗ |
| Jun 30, 2020 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts NCT01241500 · Myelodysplastic Syndromes, MDS ON 01910.Na | TRAW Traws Pharma, Inc. | Phase 3 | Completed | 299 | Oct 3, 2018 | Registry ↗ |
| Jan 10, 2018 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) NCT00854646 · Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia ON 01910.Na | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 22 | Nov 2014 | Registry ↗ |
| Jul 21, 2017 | Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients NCT00856791 · Ovarian Cancer ON 01910.Na | TRAW Traws Pharma, Inc. | Phase 2 | Completed | 1 | Jul 2011 | Registry ↗ |
| Jun 26, 2017 | Oral Rigosertib for Squamous Cell Carcinoma NCT01807546 · Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell C… rigosertib | TRAW Traws Pharma, Inc. | Phase 2 | Completed | 64 | Mar 2015 | Registry ↗ |
| Jun 26, 2017 | Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 My… NCT01584531 · Myelodysplastic Syndrome, MDS rigosertib | TRAW Traws Pharma, Inc. | Phase 2 | Completed | 82 | May 2015 | Registry ↗ |
| Jun 26, 2017 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML)… NCT01167166 · Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia rigosertib | TRAW Traws Pharma, Inc. | Phase 1/2 | Completed | 30 | Dec 2013 | Registry ↗ |
| Jun 26, 2017 | Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Cla… NCT00906334 · Myelodysplastic Syndrome ON 01910.Na, ON 01910.Na | TRAW Traws Pharma, Inc. | Phase 2 | Completed | 14 | Nov 2013 | Registry ↗ |
| Jun 26, 2017 | Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML NCT00854945 · Myelodysplastic Syndrome, Acute Myeloid Leukemia ON 01910.Na | TRAW Traws Pharma, Inc. | Phase 1/2 | Completed | 36 | Sep 2013 | Registry ↗ |
| Jun 23, 2017 | Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer NCT02107235 · Head and Neck Neoplasms, Carcinoma, Squamous Cell oral rigosertib, cisplatin | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 2 | Oct 2014 | Registry ↗ |
| Jun 23, 2017 | Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers NCT02030639 · Healthy rigosertib | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 6 | Dec 2014 | Registry ↗ |
| Jun 23, 2017 | Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer NCT01538563 · Solid Tumors, Advanced Cancer rigosertib sodium | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 42 | Jul 2010 | Registry ↗ |
| Jun 23, 2017 | Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer NCT01538537 · Advanced Cancer, Solid Tumors rigosertib sodium | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 29 | Oct 2010 | Registry ↗ |
| Jun 23, 2017 | Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors NCT01168011 · Solid Tumor rigosertib | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 68 | Dec 2015 | Registry ↗ |
| Jun 23, 2017 | Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors NCT01165905 · Solid Tumor ON 01910.Na, Gemcitabine | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 10 | Jul 2011 | Registry ↗ |
| Jun 23, 2017 | Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors NCT01125891 · Malignant Neoplasmas, Solid Tumors gemcitabine, ON 01910.Na | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 39 | Sep 2011 | Registry ↗ |
| Jun 23, 2017 | Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome NCT01048619 · Myelodysplastic Syndrome ON 01910.Na | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 36 | Nov 2014 | Registry ↗ |
| Jun 23, 2017 | Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplast… NCT00867061 · Myelodysplastic Syndrome ON 01910.Na Concentrate | TRAW Traws Pharma, Inc. | Phase 1/2 | Withdrawn | 0 | Jun 2010 | Registry ↗ |
| Jun 23, 2017 | Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma NCT00861783 · Hepatoma, Advanced Solid Tumor irinotecan and ON 01910.Na, oxaliplatin and ON 01910.Na | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 16 | Jul 2011 | Registry ↗ |
| Jun 23, 2017 | Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin NCT00861328 · Advanced Solid Tumors ON 01910.Na and irinotecan, ON 01910.Na and oxaliplatin | TRAW Traws Pharma, Inc. | Phase 1 | Completed | 18 | Jul 2011 | Registry ↗ |
| Aug 4, 2016 | Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer NCT01360853 · Metastatic Pancreatic Adenocarcinoma ON 01910.Na, Gemcitabine | TRAW Traws Pharma, Inc. | Phase 3 | Completed | 160 | Jun 2015 | Registry ↗ |
| Dec 8, 2015 | Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia NCT01049113 · Lymphoma, Acute Lymphocytic Leukemia ON 013105 | TRAW Traws Pharma, Inc. | Phase 1 | Terminated | 7 | Dec 2014 | Registry ↗ |
35 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:26 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances